Standard BioTools Inc.
NASDAQ:LABMedical - Devices
+$0.03 today
- Market cap
- $225.03M
- Beta
- 1.38
- P/E (TTM)
- -3.5
- EPS (TTM)
- -$0.24
Volume 0.70M
Average 2.91M
LAB Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
Standard BioTools Inc.NASDAQ: LAB
Net Margin · Q1 FY2026 · quarter ended Mar 2026
Net margin narrows to -213.9%
Net margin was -213.9% in Q1 FY2026, down 85.1 pp from a year earlier. On a trailing-twelve-month basis it was -109.1%, down 10.3 pp year over year. Over 3 fiscal years it widened by 106.3 pp.
Context
- Net margin widened in 1 of the last 3 fiscal years.
What to watch
Whether net margin reaches the consensus estimate from 1 analysts of -46.3% for the fiscal year ending Dec 2026, up from -87.8% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -213.9%-294.9 pp QoQ
- Last fiscal yearDec 2025
- -87.8%-8.1 pp YoY
- LTMMar 2026
- -109.1%-10.3 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -85.1 pp | +129.6 pp | +214.7 pp |
| 1 year | -8.1 pp | +41.5 pp | +49.7 pp |
| 3 years | +106.3 pp | +25.4 pp | -80.9 pp |
| 5 years | — | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -87.8%
- Year-over-year change
- -8.1pp
| Period | Period end | Net Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -87.8% | -8.1pp |
| FY2024 | 2024-12-31 | -79.6% | -9.4pp |
| FY2023 | 2023-12-31 | -70.2% | +123.9pp |
| FY2022 | 2022-12-31 | -194.1% | -148.7pp |
| FY2021 | 2021-12-31 | -45.4% | — |
Net Margin vs competitors
How LAB compares with its peers on the latest reported figures
- LAB's LTM Mar 2026 net margin of -109.1% is the 9th highest of the 10 companies compared; the peer median is -16.3%.
- Its year-over-year change of -10.3 pp is the 9th highest of 10, against a peer median of +2.8 pp.
- Over three fiscal years its change of +106.3 pp compares with a peer median of -11.8 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 4.9% | +10.8 pp | +35.0 pp | |
| LTM Apr 2026 | -9.6% | -4.6 pp | -11.8 pp | |
| LTM Mar 2026 | -9.7% | +46.1 pp | -17.1 pp | |
| LTM Mar 2026 | -15.5% | +26.1 pp | -10.7 pp | |
| LTM Mar 2026 | -16.3% | +2.8 pp | -17.8 pp | |
| LTM Mar 2026 | -29.4% | -4.3 pp | +2.4 pp | |
| LTM Mar 2026 | -36.2% | -30.5 pp | -34.6 pp | |
CBLLCeriBell, Inc. | LTM Mar 2026 | -63.5% | -0.9 pp | +83.4 pp |
| LTM Mar 2026 | -109.1% | -10.3 pp | +106.3 pp | |
| LTM Mar 2026 | -173.0% | +24.6 pp | -100.4 pp | |
| FY2025 | — | — | — | |
| Peer median (excluding LAB) | -16.3% | +2.8 pp | -11.8 pp | |
Competitors are the stored peer set for LAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 130.58M | 97.95M | 106.34M | 174.43M | 85.33M |
| Cost of Revenue | 61.21M | 60.9M | 55.89M | 90.17M | 42.79M |
| Gross Profit | 69.37M | 37.05M | 50.45M | 84.26M | 42.54M |
| Gross Margin | 53.1% | 37.8% | 47.4% | 48.3% | 49.9% |
| Research & Development | 37.94M | 37.38M | 25.95M | 62.41M | 25.99M |
| Selling, General & Admin | 98.89M | 102.29M | 87.54M | 156.61M | 109.86M |
| Operating Expenses | 136.83M | 153.26M | 127.05M | 259.5M | 135.85M |
| Depreciation & Amortization | 15.57M | 15.03M | 15.18M | 16.86M | 6.98M |
| EBITDA | (44.27M) | (173.57M) | (54.46M) | (118.14M) | (89.69M) |
| EBITDA Margin | -33.9% | -177.2% | -51.2% | -67.7% | -105.1% |
| Operating Income | (67.46M) | (116.21M) | (76.6M) | (175.24M) | (93.31M) |
| Operating Margin | -51.7% | -118.6% | -72.0% | -100.5% | -109.3% |
| Interest Income | 0 | 2.23M | 5.57M | 20.2M | 9.18M |
| Interest Expense | 3.82M | 4.33M | 4.57M | 3.32M | 26K |
| Other Income / Expenses | 3.8M | (76.72M) | 2.4M | 36.92M | (3.4M) |
| Income Before Tax | (63.66M) | (192.93M) | (74.2M) | (138.31M) | (96.7M) |
| Pre-Tax Margin | -48.8% | -197.0% | -69.8% | -79.3% | -113.3% |
| Income Tax Expense | (4.42M) | (2.83M) | 452K | 573K | (37.88M) |
| Net Income | (59.24M) | (190.1M) | (74.66M) | (138.89M) | (74.9M) |
| Net Margin | -45.4% | -194.1% | -70.2% | -79.6% | -87.8% |
| EPS (Basic) | (0.78) | (2.43) | (0.94) | (0.52) | (0.20) |
| EPS (Diluted) | (0.78) | (2.43) | (0.94) | (0.52) | (0.20) |
| Weighted Avg Shares | 75.79M | 78.31M | 79.16M | 352.67M | 381.62M |
| Weighted Avg Shares (Diluted) | 75.79M | 78.31M | 79.16M | 352.67M | 381.62M |
Standard BioTools Inc.
NASDAQ:LAB
Intrinsic Alpha fair value
Locked
Current Price
$0.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.